FULL YEAR TRADING AND OPERATIONAL UPDATE

Paris, France and Camberley, UK – 28 January 2020 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces its unaudited revenues for the year ended 31 December 2019 and provides an operational update. The Company will report its full year results in April 2020. http://novacyt.com/wp-content/uploads/2020/01/Novacyt-full-year-trading-and-operational-update-ENGLISH.pdf

Visit Page

Primerdesign partners with VGS Group in France

Commercial agreement includes molecular diagnostics for the growing aquaculture and aquamarine market Paris, France and Camberley, UK – 17 January 2020 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces its molecular testing division, Primerdesign Ltd (“Primerdesign”), has signed an exclusive commercial agreement with Atothis SARL, part of VGS Invest

Visit Page

Liquidity Agreement Monthly Update and Total Voting Rights

Paris, France and Camberley, UK – 2 January 2020 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, today announces its monthly update in relation to ordinary shares traded under its ongoing liquidity agreement with Invest Securities SA (the “Liquidity Agreement”). The Liquidity Agreement is governed by French law and is further summarised

Visit Page